Allogeneic mesenchymal stem cells therapy(Bonus BioGroup)

N/A

Report date: 2026/04/03 20:03:44

Base Information

Drug NameAllogeneic mesenchymal stem cells therapy(Bonus BioGroup)
Drug Alias NameMesenCure
ClassificationCell and gene therapy > Cell therapy > Donor > AllogeneicCell and gene therapy > Cell therapy > Stem cell therapy > Mesenchymal stem cells therapy
Mechanisms of ActionStem cell replacements
TargetsNot applicable
Therapy Area/IndicationsCoronavirus Disease 2019 (COVID-19)Diabetic FootRespiratory Distress Syndrome, Adult
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryIsrael
CombinationsNo
Global Highest StatusPhase 3 Clinical
Highest Status in ChinaN/A
Originator CompaniesBonusbio Group Ltd
China Registration ClassN/A

Develop Information

Active CompaniesSupergenics Life Science Sdn BhdBonusbio Group Ltd
Inactive CompaniesN/A
Active IndicationsCoronavirus Disease 2019 (COVID-19)Diabetic FootRespiratory Distress Syndrome, Adult
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A